$AFMD News Article - Affimed Announces Publication of Final Study Results of its Innate Cell Engager Candidate AFM13 in Combination with MSD's anti-PD-1 therapy KEYTRUDA (pembrolizumab) in Blood
https://marketwirenews.com/news-releases/affi...55862.html